Assertio Holdings (ASRT) Other Non-Current Liabilities (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Other Non-Current Liabilities came in at $4.8 million in Q1 2026, down 52.2% year-on-year from $10.1 million in Q1 2025, and down 24.07% quarter-over-quarter from $6.4 million in Q4 2025.
Assertio Holdings (ASRT) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Other Non-Current Liabilities across 8 years of filings, most recently posting $4.8 million for Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $4.8 million, down 52.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (down 52.2% YoY), and the FY2025 annual result was $6.4 million, down 37.13% from the prior year.
- Other Non-Current Liabilities came in at $4.8 million for Q1 2026 at Assertio Holdings, down from $6.4 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $26.6 million in Q1 2023 to a low of $4.3 million in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $10.1 million (2024), against an average of $12.6 million.
- Peak annual rise in Other Non-Current Liabilities reached 340.76% in 2022, while the deepest fall reached 85.72% in 2022.
- Assertio Holdings' Other Non-Current Liabilities stood at $4.3 million in 2022, then jumped by 285.55% to $16.5 million in 2023, then sank by 38.33% to $10.2 million in 2024, then sank by 37.13% to $6.4 million in 2025, then dropped by 24.07% to $4.8 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $4.8 million (Q1 2026), $6.4 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.85 Mn |
| Dec 31, 2025 | 6.38 Mn |
| Sep 30, 2025 | 8.02 Mn |
| Jun 30, 2025 | 8.91 Mn |
| Mar 31, 2025 | 10.14 Mn |
| Dec 31, 2024 | 10.15 Mn |
| Sep 30, 2024 | 16.54 Mn |
| Jun 30, 2024 | 16.38 Mn |
| Mar 31, 2024 | 16.41 Mn |
| Dec 31, 2023 | 16.46 Mn |
| Jun 30, 2023 | 5.58 Mn |
| Mar 31, 2023 | 26.60 Mn |
| Dec 31, 2022 | 4.27 Mn |
| Sep 30, 2022 | 4.39 Mn |
| Jun 30, 2022 | 23.26 Mn |
| Mar 31, 2022 | 22.86 Mn |
| Dec 31, 2021 | 4.64 Mn |
| Sep 30, 2021 | 30.76 Mn |
| Jun 30, 2021 | 5.28 Mn |
| Mar 31, 2021 | 10.64 Mn |